MedTrace Logo

Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

NCT03895502 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 605

Last updated 2023-10-04

No results posted yet for this study

Summary

The purpose of this study is to determine the optimal duration of anticoagulation therapy (3 months versus 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein thrombosis.

Conditions

  • Venous Thrombosis
  • Neoplasms
  • Anticoagulant

Interventions

DRUG

12-month Edoxaban

Prescription of Edoxaban for 12 months

DRUG

3-month Edoxaban

Prescription of Edoxaban for 3 months

Sponsors & Collaborators

  • Takeshi Morimoto

    lead OTHER

Principal Investigators

  • Takeshi Kimura, MD, PhD · Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-27
Primary Completion
2023-06-30
Completion
2023-08-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03895502 on ClinicalTrials.gov